24 January 2019 - Positive data from the phase 3 ARIEL3 clinical trial supported this expanded indication making Rubraca available to a larger patient population in an earlier line of therapy.

Clovis Oncology today announced that the European Commission has approved the use of Rubraca (rucaparib) for a second indication, as monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. 

This expands rucaparib’s indication beyond its initial marketing authorisation in Europe granted in May 2018 and with this label expansion, rucaparib is now available to patients regardless of their BRCA mutation status. Rucaparib was the first PARP inhibitor licensed for an ovarian cancer treatment indication in the EU and is now the first to be available for both treatment and maintenance treatment among eligible patients.

Read Clovis Oncology press release